Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Sales of Investments

Cash received from selling or redeeming investments.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $30.46M fell 65.3% year over year, behind the -60.2% change in trailing-twelve-month sales of investments. Sequentially, it fell 35.2% from the prior quarter. Over 3 fiscal years it compounded at -19.5% a year.

Context

  • Sales of investments amounted to 96.4% of revenue in FY2025, down 80.8 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -65.3% toward the trailing-twelve-month pace of -60.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.46M-35.2% QoQ
Last fiscal yearDec 2025
$208.24M-40.9% YoY
LTMMar 2026
$151.03M-60.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.3%——
1 year-40.9%——
3-year CAGR-19.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
208.24M USD
Year-over-year change
-40.9%
4-year CAGR
-11.8%

Sales of Investments vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 sales of investments of $151.03M is the 6th largest of the 11 companies compared; the peer median is $152.07M.
  • Its year-over-year change of -60.2% is the lowest of 9, against a peer median of -24.9%.
  • Sales of investments amounts to 69.3% of revenue for VNDA, versus a peer median of 266.8%.
VNDA Competitors Peer median
Sales of Investments for VNDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$217.57B +193061.0%+46.7%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$366.77M -26.9%+72.4%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$249.82M -36.1%-13.3%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$212.37M -43.4%+50.4%3701.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$194.74M -49.2%+73.7%533.6%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$151.03M -60.2%-19.5%69.3%
SGMTSagimet Biosciences Inc.LTM Mar 2026$109.4M +75.3%+127.7%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$31.58M -23.0%——
IMRXImmuneering CorporationLTM Mar 2026$9M -14.3%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
HUMAHumacyte, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding VNDA) $152.07M-24.9%+61.4%266.8%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Depreciation & Amortization2.84M2.73M3.01M8.13M(950K)
Deferred Income Tax6.75M1.13M(1.29M)(6.48M)81.44M
Stock-Based Compensation15.37M16.28M14.04M12.43M9.47M
Change in Working Capital2.74M6.07M(747K)(6.56M)8.31M
Accounts Receivables(2.47M)(1.09M)(707K)(13.01M)(7.46M)
Inventory(2.23M)(4.48M)(771K)(29K)(3.47M)
Accounts Payables3.04M11.79M(10.98M)1.71M15.82M
Other Working Capital4.4M(151K)11.72M4.78M3.42M
Other Non-Cash Items3.37M(507K)(4.73M)(4.38M)12.76M
Operating Cash Flow64.21M31.98M12.8M(15.76M)(109.44M)
Capital Expenditures(552K)(679K)(383K)(490K)(998K)
Acquisitions (Net)00(100.67M)(4.23M)0
Purchases of Investments(420.46M)(349.26M)(512.61M)(364.77M)(112.38M)
Sales of Investments344.32M399.86M601.6M352.06M208.24M
Other Investing Activities00000
Investing Cash Flow(76.7M)49.93M(12.06M)(17.43M)94.86M
Debt Repayment000(155K)(1.99M)
Common Stock Issued3.55M734K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(915K)
Financing Cash Flow3.55M734K0(155K)(2.91M)
Effect of Forex Changes(85K)315K47K(163K)126K
Net Change in Cash(9.02M)82.96M792K(33.51M)(17.36M)
Free Cash Flow63.66M31.31M12.42M(16.25M)(110.44M)

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.